AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16247428 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous (c.i.v.) administration of rhG-CSF
Number of subjects: 30
Study 16247428 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (s.c.) administration of rhG-CSF
Number of subjects: 30
Study 12385079 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy group (PPG)
Number of subjects: 27
Study 12385079 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior group (CBG)
Number of subjects: 27
Study 8283893 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol pretreatment
Number of subjects: 50
Study 8283893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3281489 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg over 3 days)
Number of subjects: 98
Study 3281489 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (single dose: 500 mg sulfadoxine and 25 mg pyrimethamine)
Number of subjects: 98
Study 31181957 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practice Alert (BPA)
Number of subjects: 1906
Study 31181957 — intervention group
Group type: COMPARATOR
Intervention: No Best Practice Alert (no BPA)
Number of subjects: 1906
Study 29319062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 75
Study 29319062 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (XYL)
Number of subjects: 75
Study 29319062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine + Xylitol (CHX+XYL)
Number of subjects: 75
Study 24774992 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioned group (PCG)
Number of subjects: 16
Study 24774992 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 16
Study 23855725 — intervention group
Group type: COMPARATOR
Intervention: FIFA 11+ warm-up
Number of subjects: 20
Study 21645890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐ to 3‐hour group
Number of subjects: 432
Study 21645890 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐ to 5‐hour group
Number of subjects: 432
Study 21645890 — intervention group
Group type: COMPARATOR
Intervention: 0‐ to 1‐hour group
Number of subjects: 432
Study 21645890 — intervention group
Group type: COMPARATOR
Intervention: 8‐ to 9‐hour group
Number of subjects: 432
Study 21645890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐ to 3‐hour and 4‐ to 5‐hour groups
Number of subjects: 432
Study 19826283 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction during low-intensity dynamic knee extension exercise
Number of subjects: 11
Study 19826283 — intervention group
Group type: COMPARATOR
Intervention: Nonoccluded leg during low-intensity dynamic knee extension exercise
Number of subjects: 11
Study 19826283 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (blood flow restriction and nonoccluded)
Number of subjects: 11
Study 16717297 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (10 microg, Flolan)
Number of subjects: 10
Study 16717297 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile CPB flow rates (2.4 L/min/m2 to either 1.8 or 3.0 L/min/m2)
Number of subjects: 10
Study 15058375 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) combined with surgical treatment
Number of subjects: 24
Study 15058375 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment alone (control group)
Number of subjects: 24
Study 11568950 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical method based on Cook and Weisberg's marginal model plot
Number of subjects: 0
Study 11568950 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized additive model (GAM)
Number of subjects: 0
Study 9455714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 2 mg/kg with Metoclopramide 0.2 mg/kg
Number of subjects: 100
Study 9455714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 2 mg/kg with Domperidone 0.3 mg/kg
Number of subjects: 100
Study 9455714 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 0.5 mg/kg with Metoclopramide 0.2 mg/kg
Number of subjects: 100
Study 9455714 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 0.5 mg/kg with Domperidone 0.3 mg/kg
Number of subjects: 100
Study 9455714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7956571 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 42
Study 2731781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg/day
Number of subjects: 0
Study 2731781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg/day
Number of subjects: 0
Study 2731781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1103722 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (1 mg/kg, 1-hour intravenous infusion)
Number of subjects: 12
Study 1103722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisomicin (1 mg/kg, 1-hour intravenous infusion)
Number of subjects: 12
Study 1103722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg, 1-hour intravenous infusion)
Number of subjects: 12
Study 1103722 — intervention group
Group type: EXPERIMENTAL
Intervention: All antibiotics tested
Number of subjects: 12
Study 31273773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoral nerves-2 (PECS-2) block
Number of subjects: 50
Study 31273773 — intervention group
Group type: COMPARATOR
Intervention: No block
Number of subjects: 50
Study 27916398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg twice daily
Number of subjects: 149
Study 27916398 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy (hydroxyurea, interferon, pegylated interferon, pipobroman, anagrelide, approved immunomodulators, or no cytoreductive treatment)
Number of subjects: 149
Study 27916398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 149
Study 27916398 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 149
Study 26006222 — intervention group
Group type: EXPERIMENTAL
Intervention: Dex/Bup/Fen group (1 mL epidural dexmedetomidine 0.5 µg/kg)
Number of subjects: 80
Study 26006222 — intervention group
Group type: COMPARATOR
Intervention: Bup/Fen group (intrathecal hyperbaric bupivacaine 5 mg and epidural mixture of 10 mL plain bupivacaine 0.25 % and fentanyl 50 μg)
Number of subjects: 80
Study 22674972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit® balance exercise programme (12 supervised 30-min sessions, twice a week for 6-7 weeks)
Number of subjects: 84
Study 22674972 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 84
Study 21849373 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training group with verbal instruction from a physiotherapist
Number of subjects: 18
Study 21849373 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised training group after supervised demonstration session
Number of subjects: 18
Study 18707821 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant hormonal therapy (flutamide and goserelin) before 66 Gy radiotherapy
Number of subjects: 378
Study 18707821 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 months of neoadjuvant hormonal therapy (flutamide and goserelin) before 66 Gy radiotherapy
Number of subjects: 378
Study 17594758 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide
Number of subjects: 848
Study 17594758 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marketing surveillance
Number of subjects: 848
Study 15625041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 1000
Study 15625041 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (medical counseling on diet and health without drug treatment)
Number of subjects: 1000
Study 11595000 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-142633 (50 mg)
Number of subjects: 69
Study 11595000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9558049 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/day)
Number of subjects: 12
Study 9558049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8061848 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg once daily
Number of subjects: 20
Study 8061848 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg once daily
Number of subjects: 20
Study 8061848 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 24 mg once daily
Number of subjects: 20
Study 8061848 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg once daily
Number of subjects: 20
Study 8061848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3197697 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 25
Study 3197697 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine
Number of subjects: 25
Study 31869474 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Exercise (AIEX)
Number of subjects: 44
Study 31869474 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Exercise (CEX)
Number of subjects: 44
Study 31869474 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (REX)
Number of subjects: 44
Study 31869474 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 44
Study 30304326 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored skills‐based educational intervention with telephone follow‐up
Number of subjects: 552
Study 30304326 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 552
Study 29210627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine extended release (NVP-XR) 400 mg once daily
Number of subjects: 1011
Study 29210627 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine immediate release (NVP-IR) 200 mg twice daily
Number of subjects: 1011
Study 26380444 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianjin Kouchuang Jiawei Granule (QKJG), 20 g each time, twice per day.
Number of subjects: 120
Study 26380444 — intervention group
Group type: COMPARATOR
Intervention: Kouyanqing Granule (KG), 20 g each time, twice per day.
Number of subjects: 120
Study 26380444 — intervention group
Group type: COMPARATOR
Intervention: QKJG vs KG at day 3 after treatment.
Number of subjects: 120
Study 26380444 — intervention group
Group type: COMPARATOR
Intervention: QKJG vs KG at day 7 after treatment.
Number of subjects: 120
Study 26380444 — intervention group
Group type: COMPARATOR
Intervention: QKJG vs KG at month 12 after treatment.
Number of subjects: 120
Study 23589771 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTION (n = 28)
Number of subjects: 60
Study 23589771 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 23)
Number of subjects: 60
Study 21525866 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic oligosaccharide mixture (15 or 30 g scGOS/lcFOS/pAOS daily)
Number of subjects: 57
Study 21525866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 18652320 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation at Shu- and Mu-acupoints of liver, spleen and kidney
Number of subjects: 132
Study 18652320 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Estradiol Valerate 2 mg, qd for 20 days, followed by Medroxyprogesterone Acetate 4 mg, b.i.d for 10 days
Number of subjects: 132
Study 16464714 — intervention group
Group type: EXPERIMENTAL
Intervention: PET rubidium-82 myocardial perfusion imaging
Number of subjects: 224
Study 16464714 — intervention group
Group type: COMPARATOR
Intervention: SPECT technetium-99m sestamibi myocardial perfusion imaging
Number of subjects: 224
Study 12753987 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-ml lidocaine-adrenaline injection before tonsillectomy
Number of subjects: 52
Study 10966140 — intervention group
Group type: EXPERIMENTAL
Intervention: REG at hand switch rates of 45 rpm (REG‐45)
Number of subjects: 146
Study 10966140 — intervention group
Group type: EXPERIMENTAL
Intervention: REG at hand switch rates of 60 rpm (REG‐60)
Number of subjects: 146
Study 10966140 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak REG scores
Number of subjects: 146
Study 10966140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity values of the REG test
Number of subjects: 146
Study 9264559 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery at second-look laparotomy
Number of subjects: 153
Study 1301468 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic behavior condition
Number of subjects: 155
Study 1301468 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome expectation condition
Number of subjects: 155
Study 1301468 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic behavior viewpoint condition
Number of subjects: 155
Study 1301468 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome expectation viewpoint
Number of subjects: 155
Study 1301468 — intervention group
Group type: COMPARATOR
Intervention: Non-observational control
Number of subjects: 155
Study 3551180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (KABI fragment 2165) 1 X 2'500 anti-factor Xa IU
Number of subjects: 189
Study 3551180 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 2 X 5'000 IU
Number of subjects: 189
Study 3551180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (KABI fragment 2165) 1 X 7'500 anti-factor Xa IU
Number of subjects: 189
Study 31584766 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 44
Study 31584766 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 44
Study 28399334 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction using video eyeglasses
Number of subjects: 48
Study 28399334 — intervention group
Group type: COMPARATOR
Intervention: Conventional behavior management techniques
Number of subjects: 48
Study 27112531 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira (100 U/kg, subcutaneously, 3 times per week for 28 days)
Number of subjects: 129
Study 27112531 — intervention group
Group type: COMPARATOR
Intervention: Epogen (100 U/kg, subcutaneously, 3 times per week for 28 days)
Number of subjects: 129
Study 27112531 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Number of subjects: 129
Study 27112531 — intervention group
Group type: COMPARATOR
Intervention: Epogen
Number of subjects: 129
Study 26176061 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal drainage
Number of subjects: 200
Study 26176061 — intervention group
Group type: COMPARATOR
Intervention: No abdominal drainage
Number of subjects: 200
Study 22621180 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 12.0 U
Number of subjects: 60
Study 22621180 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 7.5 U
Number of subjects: 60
Study 20193834 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (warfarin-containing regimens)
Number of subjects: 24542
Study 20193834 — intervention group
Group type: COMPARATOR
Intervention: No OAC (non-OAC regimens)
Number of subjects: 24542
Study 17894654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitemcinal 10 mg bid
Number of subjects: 106
Study 17894654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitemcinal 20 mg bid
Number of subjects: 106
Study 17894654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitemcinal 30 mg bid
Number of subjects: 106
Study 17894654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitemcinal 20 mg tid
Number of subjects: 106
Study 17894654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 15196109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg kg(‐1) bolus followed by 2 microg kg(‐1) min(‐1) infusion)
Number of subjects: 40
Study 15196109 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study 12452304 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty (group 2, n=60)
Number of subjects: 171
Study 12452304 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (group 1, n=11)
Number of subjects: 171
Study 12452304 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty (group 2) without cardiogenic shock
Number of subjects: 171
Study 12452304 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (group 1) without cardiogenic shock
Number of subjects: 171
Study 12452304 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty (group 2)
Number of subjects: 171
Study 12452304 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (group 1)
Number of subjects: 171
Study 12452304 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty (group 2) and conservative treatment (group 1) in cardiogenic shock
Number of subjects: 171
Study 9817339 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface neuromodulation via transcutaneous electrical nerve stimulation
Number of subjects: 0
Study 9817339 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation
Number of subjects: 0
Study 7711987 — intervention group
Group type: EXPERIMENTAL
Intervention: Zetir (10 mg cetirizine dihydrochloride)
Number of subjects: 14
Study 7711987 — intervention group
Group type: COMPARATOR
Intervention: Zyrtek (10 mg cetirizine dihydrochloride)
Number of subjects: 14
Study 2570799 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine, 60 mg
Number of subjects: 24
Study 2570799 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine maleate, 8 mg
Number of subjects: 24
Study 2570799 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 720103 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 0.05 ml of Finalgon Strong Ointment
Number of subjects: 51
Study 720103 — intervention group
Group type: COMPARATOR
Intervention: Brisk rubbing for 20 sec (control ear)
Number of subjects: 51
Study 31329148 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-D Stochastic Configuration Networks (2DSCNs)
Number of subjects: 0
Study 31329148 — intervention group
Group type: COMPARATOR
Intervention: 1-D Stochastic Configuration Networks (1DSCNs)
Number of subjects: 0
Study 30694974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined histamine H1 and H2 receptor antagonists (Blockade)
Number of subjects: 11
Study 30694974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 28637064 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.004 mg/kg IM)
Number of subjects: 196
Study 28637064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.0 mL normal saline solution IM)
Number of subjects: 196
Study 26089306 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS-LITE
Number of subjects: 123
Study 26089306 — intervention group
Group type: COMPARATOR
Intervention: IPS
Number of subjects: 123
Study 23985175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural patients
Number of subjects: 972
Study 20146595 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollection of objects
Number of subjects: 0
Study 20146595 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollection of faces
Number of subjects: 0
Study 20146595 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollection of words
Number of subjects: 0
Study 20146595 — intervention group
Group type: EXPERIMENTAL
Intervention: All three stimulus materials (objects, words, faces)
Number of subjects: 0
Study 20146595 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects and faces (when stimulus categories were blocked)
Number of subjects: 0
Study 19930724 — intervention group
Group type: EXPERIMENTAL
Intervention: 500,000 IU vitamin D3 (cholecalciferol) every autumn for five consecutive years
Number of subjects: 2317
Study 19930724 — intervention group
Group type: COMPARATOR
Intervention: Placebo every autumn for five consecutive years
Number of subjects: 2317
Study 15753411 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 40
Study 15753411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 40
Study 15753411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11846193 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM/P-15
Number of subjects: 25
Study 10075160 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTA vaccine at 12 months
Number of subjects: 253
Study 10075160 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTA vaccine at 15 months
Number of subjects: 253
Study 10075160 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTA vaccine at 18 months
Number of subjects: 253
Study 7669467 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg kg‐1 i.v., followed by 5 micrograms kg‐1 min‐1
Number of subjects: 24
Study 7669467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 2269712 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchangers (HME)
Number of subjects: 0
Study 2269712 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchangers (HME) after 12 hours of continuous use
Number of subjects: 0
Study 6119244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 101
Study 6119244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 31544379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding at Ganshu (BL 18), Pishu (BL 20), Sanyinjiao (SP 6), once a week for 12 weeks
Number of subjects: 92
Study 31544379 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (200 mg, 3 times a day) and Vitamin E (100 mg, once a day) for oral administration for 12 weeks
Number of subjects: 92
Study 28408148 — intervention group
Group type: EXPERIMENTAL
Intervention: Brass wire ligature treatment with mandibular third molar germectomy (group A)
Number of subjects: 14
Study 28408148 — intervention group
Group type: COMPARATOR
Intervention: Brass wire ligature treatment without mandibular third molar germectomy (group B)
Number of subjects: 14